Arcadia Biosciences Inc expected to post a loss of 29 cents a share - Earnings Preview

Arcadia Biosciences

09/11/2021 03:06

* Arcadia Biosciences Inc  RKDA.OQ   RKDA.O  is expected to show
a rise in quarterly revenue when it reports  results on November
10. 
* The Davis, California-based company is expected to report  a
698.9% increase in revenue to $2.509 million from $314 thousand
a year ago, according to the mean estimate from 2 analysts,
based on Refinitiv data. 
​* Refinitiv's mean analyst estimate for Arcadia Biosciences Inc
is for a loss of 29 cents per share. For the same quarter last
year, the company reported a loss of 60 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Arcadia
Biosciences Inc is $5.75​, about 65.9% above​ its last closing
price of $1.96. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Jun. 30 2021  -0.27       -0.27      -0.24     Beat    12.2
 Mar. 31 2021  -0.35       -0.34      0.12      Beat    135
 Dec. 31 2020  -0.41       -0.41      0.88      Beat    314.6​
 Sep. 30 2020  -0.54       -0.54      -0.60     Missed  -10.4
 ​​Jun.        -0.61       -0.59      -1.03     Missed  -75.6
 30 2020                                                
 Mar. 31 2020  -0.55       -0.54      0.29      Beat    153.2​
 Dec. 31 2019  -0.61       -0.57      -0.50     Beat    13
 Sep. 30 2019  -0.76       -0.77      -2.04     Missed  -164.9
 This summary was machine generated November 9 at 03:05 GMT.  All
figures in US dollars unless otherwise stated